Fight the Power
“We’re not going to have meaningful reforms in the cannabis space until we have more data.”
In order for a drug to get FDA approval, the data on said drug’s effects must be reviewed by the Center for Drug Evaluation & Research (CDER) and the drug must be determined to provide benefits that outweigh its known and potential risks. Now, what if research is impeded by a variety of governmental red tape? That is exactly the case with cannabis. And this is where Dr. Sue Sisley comes in. Dr. Sisley, a trailblazer in cannabis research, has been working for 14 years to push cannabis flower through the FDA drug development process – and has been hindered nearly every step of the way.
As one of the few scientists in the country holding a DEA Schedule 1 researcher license, Dr. Sisley has an intimate knowledge of not only cannabis science, but the steps it takes to conduct this kind of research. In this exclusive interview, Dr. Sisley discusses how she is helping cannabis research progress, how she’s motivating young scientists to embrace this field, and what the industry can do to help.
Cannabis & Tech Today: How did you get involved in cannabis research?
Dr. Sue Sisley: I always end up crediting military
